Paclitaxel, UFT, and calcium folinate in metastatic breast cancer

Natalie R. Dickson, Brenda P. Nicholson, Kenneth Hande, Charles Blanke, David Johnson, Alan Cohen

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.

Original languageEnglish (US)
Pages (from-to)69-70
Number of pages2
JournalONCOLOGY
Volume13
Issue number7 SUPPL.
StatePublished - Aug 20 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Paclitaxel, UFT, and calcium folinate in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Dickson, N. R., Nicholson, B. P., Hande, K., Blanke, C., Johnson, D., & Cohen, A. (1999). Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. ONCOLOGY, 13(7 SUPPL.), 69-70.